A liposomal composition (“ADx-003”) is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: ##STR00001##
wherein X is —CH.sub.2—, —CH.sub.2—CH.sub.2—, —CHO—, or —O—CO—; Y is —CH—CH═CH— or ##STR00002##
A and B are independently selected from C and N; R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently selected from —H, halogen, —OH, and —CH.sub.3; and R.sub.5, R.sub.6, and R.sub.7 are independently selected from —H, halogen, —OH, —OCH.sub.3, —NO.sub.2, —N(CH.sub.3).sub.2, C.sub.1-C.sub.6 alkyl, or a substituted or unsubstituted C.sub.4-C.sub.6 aryl group, except that when A and/or B is N the adjacent R.sub.5 and/or R.sub.7 is —H, or a pharmaceutically acceptable salt thereof.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

The present invention provides a charge-reversible phospholipid that is not positively charged at a pH of the body fluid (typically in the neutral range) and has low cytotoxicity.

The present invention provides a phospholipid represented by formula (1):

##STR00001##

wherein m represents a natural number of 9 to 25, n represents a natural number of 10 to 15, X.sub.1, X.sub.2, and X.sub.3 are the same or different and each represent H or OH, and R.sup.1 represents the following formula (i) or (ii):

##STR00002##

wherein p represents 1 or 2, q represents 1 or 2, and r represents an integer of 1 to 4; or

##STR00003##

wherein s represents an integer of 1 to 3, and R.sup.2 represents a hydrogen atom or a hydrocarbon group.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

A polymeric compound is disclosed herein, having the general formula I:

##STR00001##

wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.

The invention generally relates to methods to prevent and/or inhibit viral infection as well as to inhibit inflammation and/or pathogen infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual.

A medical lubricant may comprise a base oil. The medical lubricant can be used on a surgical device.

Ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, the compounds, compositions and methods are to provide nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.

This invention includes ionizable compounds, and compositions and methods of use thereof. The ionizable compounds can be used for making nanoparticle compositions for use in biopharmaceuticals and therapeutics. More particularly, this invention relates to compounds, compositions and methods for providing nanoparticles to encapsulate active agents, such as nucleic acid agents, and to deliver and distribute the active agents to cells, tissues, organs, and subjects.